Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Create Medicines Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 examiners and 4 art units, indicating a separate examination channel for each pending matter. That structure calls for individualized response planning and careful tracking of each examiner's treatment.
LI, RUIXIANG is the busiest examiner, with 1 pending matter. No identified examiner carries more than that pending matter, so the profile does not show a dominant examiner relationship. Counsel can still use common scientific and claim themes, but amendments should be tied to the relevant art unit and record.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §102 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LI, RUIXIANG | 1 | 59.5% | +18.7% |
| LANDSMAN, ROBERT S | 1 | 81.4% | +13.0% |
| PENNINGTON, KATIE LEIGH | 1 | 32.4% | +60.2% |
| VIVLEMORE, TRACY ANN | 1 | 72.7% | +6.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18420382 | CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER | LANDSMAN, ROBERT S | 14d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17837093 | THERAPEUTIC CELL COMPOSITIONS AND METHODS OF MANUFACTURING AND USE THEREOF | VIVLEMORE, TRACY ANN | 28d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18420382 | CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER | LANDSMAN, ROBERT S | 14d |
| 18674029 | ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | LI, RUIXIANG | — |
| 18313087 | METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION | PENNINGTON, KATIE LEIGH | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1647 | 1 |
| 1634 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18674029 | ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | LI, RUIXIANG | 1674 | §102Other | Non-Final OA | — | Pending | May 24, 2024 |
| 18420382 | CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER | LANDSMAN, ROBERT S | 1647 | §103Other | Final Rejection | 14d | Pending | Jan 23, 2024 |
| 18313087 | METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION | PENNINGTON, KATIE LEIGH | 1634 | §112 | Final Rejection | — | Pending | May 05, 2023 |
| 17837093 | THERAPEUTIC CELL COMPOSITIONS AND METHODS OF MANUFACTURING AND USE THEREOF | VIVLEMORE, TRACY ANN | 1638 | §103§112 | Non-Final OA | 28d | Pending | Jun 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCreate Medicines Inc. has 4 pending office actions as of November 2026, spread across 4 art units and 4 examiners.
Ruixiang Li has the most, with 1 of Create Medicines Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.